-
Aug 8, 2024 | 
cancernetwork.com | Scott Kopetz |Arvind Dasari |Jing Yi |Mackenzie Phillips
August 8, 2024By The panel examines challenges in interpreting circulating tumor DNA results and their impact on clinical decision-making processes. How do you factor ctDNA into treatment selection and management? How do you integrate ctDNA with radiographic or pathologic correlates? Are there challenges associated with the interpretation of ctDNA to inform your clinical decision-making? What do we know about sensitivity of ctDNA with different sites of metastatic disease?
-
Aug 8, 2024 | 
cancernetwork.com | Scott Kopetz |Arvind Dasari |Jing Yi |Mackenzie Phillips
2 Commerce Drive Cranbury, NJ 08512
-
Aug 1, 2024 | 
cancernetwork.com | Scott Kopetz |Arvind Dasari |Jing Yi |Mackenzie Phillips
2 Commerce Drive Cranbury, NJ 08512
-
Aug 1, 2024 | 
cancernetwork.com | Scott Kopetz |Arvind Dasari |Jing Yi |Mackenzie Phillips
August 1, 2024By The panel examines a clinical scenario, detailing their approach to circulating tumor DNA testing, including turnaround times, and providing insights on patient counseling. Would you offer ctDNA testing? What is the turnaround time you would expect in this case for tumor-informed assay? What would your treatment recommendation be in the absence of ctDNA results? Treatment slide questions:How would you counsel the patient? What change, if any, would you make to the treatment regimen?
-
Jul 25, 2024 | 
cancernetwork.com | Scott Kopetz |Arvind Dasari |Jing Yi |Mackenzie Phillips
July 25, 2024By Panelists analyze observed obstacles to implementing routine circulating tumor DNA testing as a standard of care, while offering strategies to overcome these challenges. What are some barriers that have been observed to implementing routine standard-of-care ctDNA testing? Do barriers differ between academic and community settings? Do you have any practical tips to navigate these barriers to implementation? Related Content Related Content
-
Jul 25, 2024 | 
cancernetwork.com | Scott Kopetz |Arvind Dasari |Jing Yi |Mackenzie Phillips
July 25, 2024By Panelists explore the clinical value of circulating tumor DNA testing at various stages of the colorectal cancer treatment journey, with a focus on optimal testing timelines. What it the clinical utility of ctDNA throughout the treatment journey for CRC? At what time points and frequency is ctDNA testing most valuable? Do the time points of these tests differ between high- and low-risk patients? Related Content Related Content
-
Jul 15, 2024 | 
cancernetwork.com | Scott Kopetz |Arvind Dasari |Jing Yi |Mackenzie Phillips
July 11, 2024By The panel examines recent studies from the INTERCEPT program investigating the utility of circulating tumor DNA (ctDNA) for minimal residual disease (MRD) detection in colorectal cancer (CRC). Please describe some recent studies exploring the utility of ctDNA in CRCDr Dasari: INTERCEPT program: ctDNA testing for MRD in CRCAssociation of positive ctDNA-based MRD assays during surveillance and undiagnosed concomitant radiographic recurrences CRC (Dasari, et al. ASCO 2023.
-
Jul 15, 2024 | 
cancernetwork.com | Scott Kopetz |Arvind Dasari |Jing Yi |Mackenzie Phillips
July 11, 2024By Key opinion leaders analyze recent findings from the BESPOKE and COSMOS studies, emphasizing new data that could potentially reshape the treatment paradigm for colorectal cancer. Dr. Kopetz: BESPOKE Interim analysis: ctDNA for informing ACT in stage II/III CRC (Kasi, et al. ASCO GI 2024.
-
Jul 8, 2024 | 
cancernetwork.com | Scott Kopetz |Arvind Dasari |Jing Yi |Mackenzie Phillips
2 Commerce Drive Cranbury, NJ 08512
-
Jun 27, 2024 | 
cancernetwork.com | Scott Kopetz |Arvind Dasari |Jing Yi |Mackenzie Phillips
June 27, 2024Arvind Dasari, MD, MS, outlines the evolution of colorectal cancer screening, addressing historical challenges, and the development of non-invasive screening techniques. Dr Dasari: Please describe the importance and a brief history of CRC screeningWhat are some challenges traditionally associated with CRC screening? Do these challenges vary between academic and community settings? How have noninvasive screening methods and age recommendations evolved over time?
